Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China | BMC Cancer | Full Text
HUTCHMED
Fruquintinib Plus Toripalimab Is an Effective Third-Line Treatment of Advanced Colorectal Cancer | Docwire News
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China | BMC Cancer | Full Text
Chi-Med goes global
Untitled
Fruquintinib: First Global Approval | SpringerLink
Suzhou Industrial Park
WuXi AppTec Partner Hutchison MediPharma Receives Approval of Fruquintinib Capsules in China | World Pharma Today
Selleck Chemical LLC Fruquintinib (HMPL-013) 5mg 1194506-26-7, Quantity: | Fisher Scientific
In Focus : Sphere eMagazine
Trinity Delta 2020 set to be the "breakthrough" year - Trinity Delta
Fruquintinib significantly extends survival in refractory metastatic colorectal cancer
Hutchmed confirms new drug application for fruquintinib in Japan - Sharecast.com
FDA Approves Fruquintinib for Metastatic Colorectal Cancer
HMP Receives Approval For Elunate | Contract Pharma
Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA's Fast Track Designation
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer | Business Wire
Hutchison MediPharma receives approval of Fruquintinib capsules in China
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study - The Lancet
HUTCHMED
China approves first "Made in China" cancer drug
